Nephrogen

Summer 2020Active

Curative genetic medicines for kidney diseases

Save

Nephrogen

Summer 2020Active

Curative genetic medicines for kidney diseases

Save

Company details

Nephrogen is a Stanford biotech spin-out developing curative genetic medicines for kidney and pancreatic diseases. Kidney disease alone affects 1 in 7 Americans, and neither indication has any approved gene-based therapies.

Nephrogen's underlying platform combines AI and high-throughput screening to engineer safer, more efficient, and less expensive gene delivery vehicles for reaching the kidney and pancreas, and has attracted non-dilutive funding from seven major pharmaceutical companies including Merck KGaA, Novartis, and Bristol Myers Squibb.

Location

New York City, NY, USA

Founded

Unknown

Request the Nephrogen report.

Nephrogen has no report yet. Sign in with your email to request one.